Scopus
Insulin detemir improves glycemic control and reduces hypoglycemia in children with type 1 diabetes: Findings from the Turkish cohort of the PREDICTIVE™ observational study
Pediatric Diabetes · Ocak 2009
Makale Bilgileri
DergiPediatric Diabetes
Yayın TarihiOcak 2009
Cilt / Sayfa10 · 401-407
Scopus ID2-s2.0-69649104020
Özet
Background: Insulin detemir is a basal insulin analog designed to produce a superior pharmacokinetic profile to basal formulations of human insulin. It has shown consistently improved tolerability in comparison to neutral protamine Hagedorn (NPH) insulin in adult cohorts, but there are relatively few publications involving pediatric cohorts. Methods: The efficacy and safety of insulin detemir in children with type 1 diabetes was assessed using data from the Turkish cohort of PREDICTIVE™ (a large, multinational, observational) study. The children investigated were using basal-bolus therapy involving NPH insulin or insulin glargine at baseline but were switched to insulin detemir as part of routine clinical care by their physicians. Results: Twelve weeks of treatment with insulin detemir significantly reduced mean hemoglobin A1c (9.7-8.9%, p < 0.001) and mean fasting glucose [185-162 mg/dL (10.3-9 mmol/L), p < 0.01]. Fasting glucose variability was also lower after treatment with insulin detemir than previously (on either NPH or glargine, p < 0.05). The frequencies of total, major and nocturnal hypoglycemic events were significantly reduced with insulin detemir relative to baseline, with an estimated mean of 6.89 fewer events/patient/yr overall (p < 0.001) and 2.6 fewer nocturnal events/patient/yr (p < 0.01). Weight and insulin dose remained relatively unchanged. Conclusions: Twelve weeks of treatment with insulin detemir improved glycemic control and reduced hypoglycemia in children with type 1 diabetes. This improved tolerability might allow further dose titration and therefore additional improvements in glucose control. © 2009 John Wiley & Sons A/S.
Yazarlar (99)
1
Selim Kurtoglu
2
M. E. Atabek
3
Ceyhun Dizdarer
4
Ozgur Pirgon
5
Pinar Isguven
6
Sevil Emek
7
M. Acar
8
G. Acarturk
9
M. Adas
10
M. Adiguzel
11
M. Akbas
12
A. Akcay
13
G. Akcay
14
S. Akcurin
15
H. Akdeniz
16
T. Akdere
17
C. Akdogan
18
G. Akoz
19
E. Aktunc
20
E. Algun
21
N. Altiner
22
Y. Altunoglu
23
M. Araz
24
C. Arilar
25
Y. Arman
26
M. Arslan
27
M. Asik
28
A. Aslan
29
I. Aslan
30
E. Atabek
31
M. Atasoy
32
H. Atmaca
33
N. Aydin
34
M. Aydin
35
I. Aykanat
36
Y. Bahceci
37
I. Bahceci
38
K. Balci
39
H. Balkanci
40
K. Basak
41
M. Bastemir
42
S. Baysal
43
S. Baysoy
44
O. Bektasyildirim
45
A. Bereket
46
O. Berker
47
N. Bilal
48
O. Bilgir
49
I. Bircan
50
F. Bulduk
51
A. Büyükbese
52
A. Buyukgediz
53
S. Caglayan
54
S. Cakir
55
H. Cakir
56
H. Calikusu
57
S. Can
58
N. Caneroglu
59
A. Catan
60
T. Cavusxoǧlu
61
M. Cebi
62
T. Cecen
63
A. Celebi
64
A. Celik
65
M. Cesur
66
S. Cetin
67
B. Cetinarslan
68
S. Cetinkalp
69
M. Cevik
70
E. Cevizci
71
A. Cokay
72
Y. Colakoglu
73
H. Comert
74
R. Conkar
75
M. Davutoglu
76
A. Dayan
77
S. Demirel
78
R. Demirtunc
79
Z. Deniz
80
D. Dereli
81
S. Dileklen
82
I. Dinc
83
S. Dinc
84
M. Dogan
85
S. Dokmetas
86
M. Donmez
87
B. Dundar
88
C. Duygulu
89
M. Ecer
90
I. Emir
91
C. Emiroglu
92
E. Emrullah Demirel
93
F. Erdemir
94
M. Ergoz
95
T. Erkenez
96
A. Erol
97
E. Erorer
98
R. Ersoy
99
C. Erten
Anahtar Kelimeler
Diabetes mellitus type 1
Hypoglycemia
Insulin detemir
Pediatric
Kurumlar
Behcet Uz Children's Hospital
Izmir Turkey
Erciyes University, Faculty of Medicine
Kayseri Turkey
Novo Nordisk A/S
Bagsvard Denmark
Selçuk Üniversitesi
Selçuklu Turkey
T.C. Saglik Bakanligi Istanbul Goztepe Egitim ve Arastirma Hastanesi
Goztepe Turkey
Metrikler
14
Atıf
99
Yazar
4
Anahtar Kelime